We suggest that investors who own GSK's stock remain invested for now, considering its sales and profits are expected to continue improving in the coming years.

Electrovaya's strong financial position and industry-leading cycle life are key growth drivers. Find out why ELVA stock is a ...

Millions of Americans will receive a tax refund when they file their taxes this year, giving them a nice cash boost that can ...

There is a Wall Street financial generalization that still rings true a majority of the time: portfolios should focus on ...

Bank of New York Mellon Corp lifted its stake in shares of Novavax, Inc. (NASDAQ:NVAX – Free Report) by 0.4% during the ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Sanofi to acquire Dren Bio's bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline Dren Bio deep B-cell depleter program has the potential to reset the immune syste ...